Unknown

Dataset Information

Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.


ABSTRACT:

Background

Malignant pleural mesothelioma (MPM) is well known as an aggressive disease with poor survival. This has sparked trials of alternate immune-based therapies in MPM. While up to a quarter of MPM patients respond to immune checkpoint inhibitors (ICIs), predicting response remains challenging and PD-L1 expression alone has been deemed insufficient. Additionally, patients with sarcomatoid MPM are often excluded from trials utilizing ICIs due to their rapid progression. Here, we analyze the association of T lymphocytes with response to ICI-based immunotherapy to uncover predictive immune markers across subtypes.

Methods

Retrospective analysis of immunotherapy treated mesothelioma patient cohorts from two sites were pooled. Patient characteristics, including age, sex, su

SUBMITTER: Brockwell NK 

PROVIDER: S-EPMC7354134 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature